BIOSIM Act

Summary

Bolstering Innovative Options to Save Immediately on Medicines Act or the BIOSIM Act This bill increases Medicare payments for biosimilars for five years. The bill applies to biosimilars for which the average sales price or wholesale acquisition cost is less than that of the reference biological product, as specified.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 22 April 2021

   Referred

   Referred to the Subcommittee on Health.

   Source: Committee

2. 22 April 2021

   Introduced

   Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

   Source: IntroReferral

3. 22 April 2021

   Introduced

   Introduced in House

   Source: IntroReferral

4. 22 April 2021

   Introduced

   Introduced in House

   Source: IntroReferral

5. 23 April 2021

   Referred

   Referred to the Subcommittee on Health.

   Source: Committee

Votes

No vote records are attached yet.

Versions

• Introduced in House · 22 April 2021 · Official file

Documents

3 official files

• Introduced in House (text)

  Introduced in House · EN · 22 April 2021

  ViewDownloadOpen at official source

• Introduced in House (PDF)

  Introduced in House · EN · 22 April 2021

  ViewDownloadOpen at official source

• Introduced in House

  summary · EN · 22 April 2021

  Open at official source

Sponsors

• Kurt Schrader · D · Sponsor
• Adam Kinzinger · R · Sponsor
• Mikie Sherrill · D · Cosponsor
• G. K. Butterfield · D · Cosponsor
• Kim Schrier · D · Cosponsor
• · hsif00 · Standing
• · hswm00 · Standing

Related records

• related to ← An act to provide for reconciliation pursuant to title II of S. Con. Res. 14.
• related to ← Make Medicine Affordable Act
• related to ← BIOSIM Act